N/A N=45 Pilot Trial of a Novel Cooking Skills Intervention (DPPCooks) to Prevent Diabetes
Pre-diabetes
Primary: Change From Baseline in Absolute Body Weight (Kilograms (kg)) — -2.12; -1.00; -5.27; -4.15 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
COL6A3 Positive · HLA-A*0201 Positive Cells Present · PRAME Positive
Primary: Assess Safety and Toxicity of Adoptively Transferred Central Memory-type CTL Targeting Ovarian Cancer Antigens Administered Alone, and in Combination With, Utomilumab…
Phase 2 N=72 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Primary: Percentage of Participants Achieving Disease Control at or Before 12 Weeks — 13.6; 50.0; 35.0; 35.7 percentage of participants
N/A N=10 PIMPmyHospital: a Mobile App to Improve Emergency Care Efficiency and Communication
Pediatric Emergency Medicine · Communication
Primary: Time to Laboratory Results — 1; 23 Minutes
Phase 2 N=40 APBI Proton Feasibility and Phase II Study
Stage IA-IIA Breast Cancer
Primary: Feasibility and the Acute Toxicity Profile of Accelerated Partial Breast Radiation Using Protons — 11; 0; 0; 0 Participants
Phase 4 N=23 Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)
Eosinophilic Esophagitis
Primary: Percent of Patients in Remission at One Year as Measured by EGD — 5; 1 Participants — p=0.57
Phase 1 N=18 Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition
Healthy Participants
Primary: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for Bosutinib — 3312; 3205; 3161 nanogram•hour per milliliter (ng•hr/mL)
Phase 2 N=52 A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
Hepatitis D, Chronic
Primary: Double-blind: Part 1: Percentage of Participants With HDV Ribonucleic Acid (RNA) >=2 log10 IU/mL Decline From Baseline or HDV RNA Target Not Detected (TND) in…
Phase 1 N=66 Marijuana in Combination With Opioids in Palliative and Hospice Patients
Pain
Primary: Primary Reduction of Pain — 2.55; 1.40 units on a scale from 0 to 10
N/A N=161 Youth-friendly Sexual and Reproductive Healthcare Pilot in Mumbai, India
Reproductive Health
Primary: Change in Sexual and Reproductive Health and Rights Knowledge Survey Score — 0.45; 0.44; 0.47; 0.49 score on a scale
Phase 4 N=101 Comparing Effectiveness of CSE Versus DPE for Labor Analgesia
Labor Pain
Primary: Number of Participants With the Presence of Any of the Five Block Quality Components (or More Than One) — 16; 13 Participants — p=0.486
N/A N=518 X-3 Polyethylene Survival Outcomes Study
Arthroplasty, Replacement, Knee · Total Knee Replacement
Primary: Prosthesis Survivorship Free of Revision — 96; 97 percentage of prosthesis survivorship — p=0.47
Phase 2 N=25 Use of a GLP-1R Agonist to Treat Opioid Use Disorder
Opiate Substitution Treatment · Opioid-Related Disorders
Primary: Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS) — -5.00; -13.34 score on a scale
Phase 3 N=851 A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
Carcinoma, Squamous Cell, Non-small-cell Lung
Primary: Progression-free Survival (PFS) — 8.3; 5.4 Months — p=0.0040
N/A N=333 Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System
Abdominal Aortic Aneurysm (AAA)
Primary: Major Adverse Events at 30 Days — 4; 1; 2 Participants